The Clinical Candidate, Astx029, Is A Novel, Dual Mechanism Erk1/2 Inhibitor And Has Potent Activity In Mapk-Activated Cancer Cell Lines And In Vivo Tumor Models J. Munck,V. Berdini,A. Courtin, C. East,T. Heightman,C. Hindley, J. Kucia-Tran,J. Lyons,V. Martins,S. Muench, C. Murray, D. Norton, M. O’Reilly, M. Reader,D. Rees,S. Rich,N. Thompson, N. Wilsher,A. Woolford,N. WallisEUROPEAN JOURNAL OF CANCER（2020）引用 0|浏览34暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
